The lodenafil carbonate in the treatment of erectile dysfunction;Carbonato de lodenafila no tratamento da disfunção erétil

Revista Brasileira de Medicina

Volumn 64, Issue 9, 2007, Pages 425-432

  Galvão Lúcio, Luiz Antônio ^a   Pagani, Eduardo ^b   Barros Afìune, Jorge ^c  

^a Laboratório Cristália

^b Pesquisa Clinica

^c Laboratório Cristália

Author keywords

Erectile dysfunction; Lodenafil carbonate; PDE 5; Phosphodiesterase inhibitor

Indexed keywords

LODENAFIL CARBONATE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FATIGUE; FLUSHING; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RHINITIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 35548975112     PISSN: 00347264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Moreira ED Jr, Bestane WJ, Bartolo EB, Fittipaldi JA. Prevalence and determinants of erectile dysfunction in Santos, southeastern Brazil. São Paulo Med J. 2002;120(2):49-54.
2. Moreira ED Jr., Lobo CF, Diament A, Nicolosi A, Glasser DB. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology 2003;61(2):431-6.
3. Nicolosi A, Moreira ED Jr, Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology 2003;61(1):201-6.
4. Shiri R, Koskimaki J, Hakama M, Hakkinen J, Tammela TL, Huntala H, Auvinen A. Effect of chronic diseases on incidence of erectile dysfunction. Urology 2003;62(6):1097-102.
5. Stein RA. Managing concomitant cardiac disease and erectile dysfunction. Rev Urol 2002;4 Suppl 3: S39-47.
6. Moreira ED; Abdo CH, Torres EB; Lôbo CF, Fittipaldi JA. Prevalence and correlates of erectile dysfunction: results of the Brazilian study of sexual behavior. Urology 2001; 58(4): 583-8.
7. Brant WO, Bella AJ, Lue TF. Treatment options for erectile dysfunction. Endocrinol Metab Clin North Am 2007;36(2): 465-79.
8. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry and Reviewers. Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers. Avaiable from: http://www.fda.gov/cber/gdlns/dose.pdf_(23 apr 2007).
9. Seftel AD. Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases. Curr Pharm Des 2005; 11(31): 4047-58.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.